Summary - Fundamenty - Všechna data pro vaši analýzu

Nástroje

Akciový screener

Kalendář zisků

Super investoři

Ostatní

Návod

IČ: 19940963

5. května 521, 501 01 Turnov

Zásady GDPR

Podmínky služby

Všechna práva vyhrazena @ 2024, Fundamenty.cz

Proudly created by draftspot.net

Agios Pharmaceuticals, Inc.

AGIO

Valuace

Růst

Zdraví

Cena

$ 36.09

-0.61 (-2.19%)

Kapitalizace

2.4B

Obrat

Zisk

Aktiva

Dluh

ROE

ROA

-4

Cena 1R

22-46

⌀ Cena

34.06

Dividenda

0.0(0.0%)

Čtvrtletní 10-Q

Celoroční 10-K

Nadcházející oznámení zisků

Poslední dividenda

Profil

Agios Pharmaceuticals, Inc., biofarmaceutická společnost, se zabývá objevováním a vývojem léčiv v oblasti buněčného metabolismu a přilehlých oblastech biologie. Společnost nabízí PYRUKYND (mitapivat) aktivátor jak divokého typu, tak různých mutantů pyruvát kinázy, PK, enzymů pro léčbu hemolytických anémií; a AG-946, který je ve fázi I klinické studie pro léčbu hemolytických anémií a dalších indikací. Společnost Agios Pharmaceuticals, Inc. byla založena v roce 2007 a sídlí v Cambridge v Massachusetts.

Sektor

Healthcare

Odvětví

Biotechnology

Počet zaměstnanců

486

Založení

2013-07-24

Adresa

88 Sidney Street

CEO

Brian M. Goff

Web

www.agios.com

Podobné společnosti

DNLI

Denali Therapeutics Inc.

$ 16.13

+ $ 1.11

RXRX

Recursion Pharmaceuticals, Inc.

$ 4.52

- $ 0.10

BEAM

Beam Therapeutics Inc.

$ 21.90

- $ 0.31

RCUS

Arcus Biosciences, Inc.

$ 19.95

+ $ 0.64

ETNB

89bio, Inc.

$ 14.84

+ $ 0.00

COGT

Cogent Biosciences, Inc.

$ 33.20

+ $ 18.38

IBRX

ImmunityBio, Inc.

$ 2.15

+ $ 0.02

Zahraniční články

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

12:08 31-03-2026

Agios Pharmaceuticals' mitapivat has shown tremendous promise as a treatment for sickle cell disease...

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

12:03 31-03-2026

2,959 shares sold for a total of ~$82,000 at a weighted average price of around $27.80 per share on ...

AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money

9:00 31-03-2026

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to sharehold...

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

8:45 31-03-2026

With physicians identifying up to one-third of patients as candidates, early adoption reflects stron...

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

7:00 31-03-2026

Company has already submitted proposed confirmatory trial for FDA review, as required under accelera...

Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.

3:32 31-03-2026

Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDA...

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

9:00 25-03-2026

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced a...

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

9:00 17-03-2026

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to sharehold...

ArrowMark Colorado Holdings LLC Has $27.29 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO

4:24 15-03-2026

ArrowMark Colorado Holdings LLC increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ...

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

9:00 11-03-2026

NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced a...

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

9:00 10-03-2026

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to sharehold...

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

9:00 04-03-2026

NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced a...

Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO

9:00 03-03-2026

NEW YORK, March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholde...

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

7:00 26-01-2026

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a co...

Výsledovka

Rozvaha

Peněžní toky

Nástroje

Ostatní

Profil

Podobné společnosti

Zahraniční články

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

ArrowMark Colorado Holdings LLC Has $27.29 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Výsledovka

Rozvaha

Peněžní toky